Related Articles
Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review
Primary signet‑ring cell carcinoma of the lung treated with crizotinib: A case report